Supernus Pharmaceuticals, Inc.
https://www.supernus.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Supernus Pharmaceuticals, Inc.
Was Apokyn Safety Update A Missed Opportunity For Supernus To Hold Off Generic Refill Cartridge?
US FDA told the company to add a warning to the label in late January, about a month before the generic refill cartridge was approved.
Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.
Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Other Names / Subsidiaries
-
- Adamas Pharmaceuticals, Inc.
- Biscayne Neurotherapeutics, Inc.
- Biscayne Neurotherapeutics Australia Pty, Ltd
- Shire plc
- Shire Laboratories Inc